Citius Oncology (CTOR) Net Cash Flow (2023 - 2026)

Citius Oncology (CTOR) posted quarterly Net Cash Flow of -$4.7 million for Q1 2026, down 238.34% quarter-over-quarter from $3.4 million in Q4 2025.

Citius Oncology (CTOR) Net Cash Flow (2023 - 2026) Analysis & Trends

Citius Oncology (CTOR) has reported Net Cash Flow for 4 consecutive years, with -$4.7 million the latest figure, recorded in Q1 2026.

In Q1 2026, Net Cash Flow changed N/A year-over-year to -$4.7 million; the TTM figure through Mar 2026 stood at -$1.3 million (down 3807.81% YoY), while the FY2025 annual figure was $3.9 million, up 3504182.14% from the prior year.
Net Cash Flow declined to -$4.7 million in Q1 2026 per CTOR's latest filing, from $3.4 million in the prior quarter.
Across five years, Net Cash Flow topped out at $3.4 million in Q4 2025 and bottomed at -$4.7 million in Q1 2026.
Historically, Net Cash Flow has averaged -$265209.4 across 4 years, with a median of -$100256.0 in 2023.
On a YoY basis, Net Cash Flow climbed as much as 100.35% in 2024 and fell as far as 67.02% in 2024.
Citius Oncology's Net Cash Flow stood at -$262652.0 in 2023, then surged by 87.41% to -$33069.0 in 2024, then soared by 10292.46% to $3.4 million in 2025, then tumbled by 238.34% to -$4.7 million in 2026.
Business Quant data shows CTOR's Net Cash Flow at -$4.7 million in Q1 2026, $3.4 million in Q4 2025, and -$33069.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Cash Flow (Qtr)
1	Haleon	43.94 Bn	42.97 Bn	-	-
2	Teva Pharmaceutical Industries	43.08 Bn	39.43 Bn	2.15 Bn	-81.00 Mn
3	Zoetis	31.54 Bn	29.87 Bn	1.05 Bn	-458.00 Mn
4	Takeda Pharmaceutical	28.60 Bn	22.80 Bn	5.10 Bn	-881.03 Mn
5	United Therapeutics	22.12 Bn	19.46 Bn	683.80 Mn	523.50 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn	-912.40 Mn
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn	64.40 Mn
8	Elanco Animal Health	11.69 Bn	11.16 Bn	798.00 Mn	93.00 Mn
9	Dr Reddys Laboratories	10.13 Bn	9.96 Bn	-	-
10	Citius Oncology	81.99 Mn	81.99 Mn	1.00 Mn	13.93 Mn

Download Data